吉利德:Trop2 ADC一线治疗HR+/HER2-乳腺三期临床失败

医药笔记
Nov 08, 2025

▎Armstrong2025年11月7日,吉利德宣布Trop2 ADC新药Trodelvy对比化疗一线治疗内分泌治疗后HR+/HER2-乳腺癌的三期临床ASCENT-07没有达到PFS主要终点,关键次要终点OS尚未成熟,但观察到获益趋势,研究将继续进行以评估OS数据。Trodelvy 2024年销售额为13.15亿美元,2025年前三季度销售额为10.14亿美元,在二线三阴乳腺癌市场占据第一位的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10